Holen Sie sich die Stockscreener-App
1.70
1.73%
-0.03
Handel nachbörslich:
1.71
0.01
+0.59%
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
How Citius Oncology Inc. stock benefits from tech adoption2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Real time breakdown of Citius Oncology Inc. stock performancePortfolio Gains Report & Risk Managed Investment Strategies - newser.com
What analysts say about Citius Oncology Inc stockCurrency Fluctuation Impact & High Return Wealth Building - earlytimes.in
Why Citius Oncology Inc. stock is recommended by analysts2025 Analyst Calls & Reliable Trade Execution Plans - newser.com
Sector ETF performance correlation with Citius Oncology Inc.Trade Analysis Summary & Short-Term High Return Strategies - newser.com
What to do if you’re stuck in Citius Oncology Inc.Trade Volume Report & High Return Stock Watch Alerts - newser.com
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Is Citius Oncology Inc. stock attractive for long term wealth buildingBuy Signal & Fast Moving Stock Watchlists - newser.com
Is Citius Oncology Inc. stock bottoming out2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Is it too late to sell Citius Oncology Inc.July 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
Is Citius Oncology Inc. a candidate for recovery playStock Surge & Safe Swing Trade Setup Alerts - newser.com
Heatmap analysis for Citius Oncology Inc. and competitors2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Citius Oncology's (CTOR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
How Citius Oncology Inc. stock performs in stagflationTrade Risk Summary & Low Drawdown Trading Strategies - newser.com
Will a bounce in Citius Oncology Inc. offer an exitMarket Movement Recap & Safe Entry Zone Identification - newser.com
Has Citius Oncology Inc. formed a bullish divergenceVolume Spike & Daily Volume Surge Signals - newser.com
Is it time to cut losses on Citius Oncology Inc.Trade Volume Report & Real-Time Stock Price Movement Reports - newser.com
Citius in talks over Lymphir access in global markets - The Pharma Letter
Citius Oncology expands LYMPHIR access through named patient programs By Investing.com - Investing.com Canada
Citius Sets Up Access to Lymphir in Southern Europe - MarketScreener
Citius Oncology expands LYMPHIR access through named patient programs - Investing.com
Citius Oncology enters exclusive distribution agreement with Integris Pharma S.A. - MarketScreener
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - PR Newswire
Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Decline in Short Interest - Defense World
Is a relief rally coming for Citius Oncology Inc. holdersWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
Can volume confirm reversal in Citius Oncology Inc.July 2025 Highlights & Low Risk Entry Point Tips - newser.com
Using data tools to time your Citius Oncology Inc. exit2025 Earnings Impact & Technical Analysis for Trade Confirmation - newser.com
What MACD and RSI say about Citius Oncology Inc.Trade Risk Report & Long-Term Safe Return Strategies - newser.com
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Down 55.2% in September - MarketBeat
Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey - Defense World
Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - Nasdaq
0.90%
2.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):